Standout Papers
- Isolation of isoflavonoids possessing antioxidant activity from the fermentation broth of Streptomyces sp. (1989)
- Structural study of isoflavonoids possessing antioxidant activity isolated from the fermentation broth of Streptomyces sp. (1989)
- Structure-activity relationship of a novel antitumor ansamycin antibiotic trienomycin A and related compounds. (1988)
Citation Impact
Citing Papers
Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers
2006
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
TOR Signaling in Growth and Metabolism
2006 Standout
Incorporation of sensing modalities into de novo designed fluorescence-activating proteins
2021 StandoutNobel
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
2012 Standout
Lysyl Oxidase Binds Transforming Growth Factor-; and Regulates Its Signaling via Amine Oxidase Activity
2008
Gastric cancer
2016 Standout
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
2016
Vismodegib
2012
Design and synthesis of ansamycin antibiotics
2008
Smarter drugs emerging in pancreatic cancer therapy
2014
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
1998
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens
1998 StandoutNobel
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Targeted delivery of platinum-based anticancer complexes
2013
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
2003 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Regulation of microRNA biogenesis
2014 Standout
The dual role of thymidine phosphorylase in cancer development and chemotherapy
2009
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
Targeted therapy using nanotechnology: focus on cancer
2014
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
2012
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Modulation of gene expression in transgenic mouse hearts overexpressing calsequestrin
2002
Targeting mammalian target of rapamycin (mTOR) for health and diseases
2006
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Lysyl oxidases: A novel multifunctional amine oxidase family
2001
Current development of mTOR inhibitors as anticancer agents
2006
‘See-saw’ expression of microRNA-198 and FSTL1 from a single transcript in wound healing
2013 Nature
Nanoparticle uptake: The phagocyte problem
2015
Nanocarriers for delivery of platinum anticancer drugs
2013
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
2008 Standout
Colorectal cancer
2019 Standout
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Calcium Affinity, Cooperativity, and Domain Interactions of Extracellular EF-hands Present in BM-40
2000
Trends in the search for bioactive microbial metabolites
1992 StandoutNobel
Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease
2010 Standout
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
2007 Standout
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Phenopyrrozin, a New Radical Scavenger Produced by Penicillium sp. FO-2047.
1995 StandoutNobel
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
mTOR-targeted therapy of cancer with rapamycin derivatives
2005
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
2000
Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
2012
Update on tubulin-binding agents
2005
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
2004
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
2005
Structure and Spectroscopy of Copper−Dioxygen Complexes
2004 Standout
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
(+)-Mycotrienins I and II: Relative and Absolute Stereochemistry
1991 StandoutNobel
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Isolation and structure determination of (+)-trienomycin F. An endgame synthetic strategy for the trienomycin family of antitumor antibiotics
1991 StandoutNobel
The Type 1 Insulin-Like Growth Factor Receptor Pathway
2008
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
2011 StandoutNobel
Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene
2004 StandoutNobel
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Production of hydrogen peroxide by transforming growth factor-beta 1 and its involvement in induction of egr-1 in mouse osteoblastic cells.
1994
Requirement for Generation of H 2 O 2 for Platelet-Derived Growth Factor Signal Transduction
1995 StandoutScience
Inductively coupled nanocomposite wireless strain and pH sensors
2008
Extracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators
2002
(+)-Trienomycins A, B, C, and F and (+)-Mycotrienins I and II: Relative and Absolute Stereochemistry
1996 StandoutNobel
Inhibitors of the mammalian target of rapamycin
2005
Light-Controlled Radical Polymerization: Mechanisms, Methods, and Applications
2016 Standout
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
2006
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
2008
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Confinement-Controlled, Either syn- or anti-Selective Catalytic Asymmetric Mukaiyama Aldolizations of Propionaldehyde Enolsilanes
2021 StandoutNobel
Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation
2011
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
2006
25th Anniversary Article: The Evolution of Electronic Skin (E‐Skin): A Brief History, Design Considerations, and Recent Progress
2013 Standout
Works of Akira Mita being referenced
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
2008
Cloning from a mouse osteoblastic cell line of a set of transforming‐growth‐factor‐β1‐regulated genes, one of which seems to encode a follistatin‐related polypeptide
1993
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumors
2006
Isolation of isoflavonoids possessing antioxidant activity from the fermentation broth of Streptomyces sp.
1989 StandoutNobel
Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats
1996
Structure-activity relationship of a novel antitumor ansamycin antibiotic trienomycin A and related compounds.
1988 StandoutNobel
Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging
2004
Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation.
2011
Structural study of isoflavonoids possessing antioxidant activity isolated from the fermentation broth of Streptomyces sp.
1989 StandoutNobel
Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors
2004
A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors.
2010
<title>Health monitoring of smart structures using damage index sensors</title>
2002
A smart sensor using a mechanical memory for structural health monitoring of a damage-controlled building
2003
Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies
2004
A phase IB trial of iniparib (BSI-201) in combination with carboplatin (C)/paclitaxel (P) in patients with non-small cell lung cancer (NSCLC).
2011
Phase I/II study of TH-302 in combination with gemcitabine in patients with solid tumors including advanced pancreatic cancer.
2010
A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G)
2008
A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
2009
Damage index sensor for smart structures
2004
Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors
2004